Document is current
Any future updates will be listed below
-
Authors
Kim, Kyungsoo
Park, Seyeon
Park, Seong Yong
Kim, Gamin
Park, Su Myeong
Cho, Jae-Won
Kim, Da Hee
Park, Young Min
Koh, Yoon Woo
Kim, Hye Ryun
Ha, Sang-Jun
Lee, Insuk https://orcid.org/0000-0003-3146-6180
-
Funding
Funding for this research was provided by:
National Research Foundation of Korea (2018M3C9A5064709, 2018R1A5A2025079)
National Research Foundation of Korea (2019M3A9B6065189, 2017R1A5A1014560, 2018M3A9H3024850, 2018R1A2A1A05076997, 2019M3A9B6065221)
- License Information
-
More Information
Article History
Received: 3 December 2019
Accepted: 9 February 2020
First Online: 28 February 2020
Ethics approval and consent to participate
: The studies were approved by the Institutional Review Board of Yonsei University Severance Hospital with IRB no. 4-2016-0678 for the 16 NSCLC patients undergoing anti-PD-1 treatment and IRB no. 4-2016-0788 for the 35 patients with NSCLC and 15 patients with HNSCC. All patients who participated in these studies provided written informed consent prior to enrollment and sample collection at Yonsei University Severance Hospital. The research conformed to the principles of the Helsinki Declaration.The mice were maintained in accordance with the Laboratory Animals Welfare Act, the Guide for the Care and Use of Laboratory Animals, and the Guidelines and Policies for Rodent Experiments proposed by the Institutional Animal Care and Use Committee (no. IACUC-A0201809-787-01) of the Yonsei University Health System.
: Not applicable.
: The authors declare that they have no competing interests.
